Combination therapy and antibody panels

Details Combination therapy and antibody panels Combination therapy and antibody panels

A - Human Necessities

61

K

A61K 39/00 (2006.01) A61K 39/395 (2006.01)

Patent

CA 2632744

The present invention is related to combination immunotherapy for malignancies such as Non-Hodgkin's Lymphoma (NHL) and chronic lymphocytic leukemia (CLL). In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody, or antibody fragment, directed to a non-idiotypic portion of an immunoglobulin or immunoglobulin-like molecule expressed on the surface of a malignant cell (e.g., a framework region of a variable region). The combination immunotherapy next provides for the administration of an immunogenic composition comprising at least a portion of the same malignant cell surface immunoglobulin, whether an idiotypic portion or non-idiotypic portion.

La présente invention concerne une immunothérapie combinée pour des cellules malignes de type lymphome non Hodgkinien (LNH) et leucémie lymphocytique chronique (LLC). Dans un mode de réalisation, l'immunothérapie combinée consiste d~abord à administrer un anticorps monoclonal, ou un fragment d'anticorps, dirigé contre une partie non idiotypique d'une immunoglobuline ou d~une molécule semblable à une immunoglobuline exprimée sur la surface d'une cellule maligne (par exemple, une région de structure d'une région variable). L'immunothérapie combinée consiste ensuite à administrer une composition immunogénique qui comprend au moins une partie de la même immunoglobuline de surface de la cellule maligne, que ce soit une partie idiotypique ou partie non idiotypique.

Affiliated with

Also associated with

Rating

Combination therapy and antibody panels does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy and antibody panels, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy and antibody panels will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1664617